#United States #Los Angeles #Cenobamate #SK Life Science #Epilepsy Society

SK Life Science's Presentation on Cenobamate Research at AES

At the upcoming 2024 American Epilepsy Society (AES) Annual Meeting, scheduled from December 6-10 in Los Angeles, California, SK Life Science, Inc. will unveil updated data regarding cenobamate, a medication designed to manage seizures effectively. As a prominent entity in the sphere of central nervous system disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., SK Life Science aims to enhance the dialogue surrounding anti-seizure therapies with new evidence and insights.

One of the focal points during this year's AES will be the symposium titled 'Prioritizing Seizure Treatments Through Real-World Patient Case Studies.' This expert-led panel is created to explore the challenges patients encounter in their quest for seizure freedom. Louis Ferrari, BS, RPh, MBA, who serves as the vice president of Medical Affairs at SK Life Science, emphasized the importance of understanding the continuous struggle for seizure freedom faced by many epilepsy patients. The company’s aim is to equip healthcare professionals with updated strategies and significant data that can address diverse patient needs effectively.

The symposium will kick off on Friday, December 6, at 6:00 p.m. PT at the JW Marriott in Los Angeles. Participants will delve into the unmet needs of patients struggling to achieve seizure freedom and will focus on identifying individuals who may benefit from treatment modifications. Moreover, the symposium will shed light on the challenges posed by recurring seizures and suggest optimized treatment regimens to enhance early efficacy while reducing the need for additional medications.

Three distinguished epileptologists will be leading the session:

• - David Vossler, MD, FAAN, FAES, FACNS from the University of Washington.
• - Danielle Becker, MD, MS, FAES from The Ohio State University Wexner Medical Center.
• - Mohammad Koubeissi, MD, FAAN, FANA, FAES from the George Washington University.

In addition to the symposium, SK Life Science will also participate in multiple poster presentations throughout the AES conference. Topics will cover a range of studies related to cenobamate, including:

• - Efficacy and Safety of Adjunctive Cenobamate in Asian Patients with Focal Seizures
• - Early Response Rates with Adjunctive Cenobamate in Uncontrolled Focal Seizures
• - Understanding the Mechanism of Action of Cenobamate

These sessions are aimed at fostering a deeper understanding of how cenobamate operates within different patient populations.Clinicians and researchers attending the AES will have the opportunity to view these presentations and engage with the data presented.

SK Life Science is committed to advancing treatments for epilepsy. With over 3.4 million individuals living with this neurological disorder in the United States alone, the importance of effective seizure management is paramount. Despite the availability of numerous anti-seizure medications, almost 40% of individuals with epilepsy are unable to reach seizure freedom, underscoring a critical need for ongoing research and innovation.

The presentations and symposium are just a part of SK Life Science’s ongoing mission to bring groundbreaking treatments to market while ensuring that physicians have access to the best information possible. By facilitating discussions among experts and practitioners, they aim to innovate strategies that improve the lives of those living with epilepsy.

To learn more about cenobamate or to register for the upcoming AES symposium, interested individuals can visit the official website of SK Life Science or the AES conference site. Ensuring that patients receive the most effective treatments remains a priority for the organization, and they are excited to share their latest findings at this highly anticipated annual meeting.